• Histology data not reported• Germline BRCA1/2-mutated advanced ovarian cancer• ≥3 prior lines of chemotherapy• Platinum-resistant (59%)• Platinum-refractory (10%)• Platinum-sensitive (28%). This evidence concerns the gene BRCA1 and ovarian carcinoma.